Heart Failure Drug Development Might Need A Good Lawyer After US FDA Guidance
With draft guidance allowing for drugs that improve heart failure symptoms but do not improve – or may even decrease – survival, the legal community could help establish development metrics.
You may also be interested in...
Pathologic complete response eventually may be a surrogate endpoint for survival, but researchers and the US FDA outlined several problems that must be resolved first.
The concept of missing data is very different when analyzing real-world evidence compared to a randomized clinical trial.
As more sponsors begin using RWE, the agency is establishing procedures and training to ensure assessors consistently apply policies.